Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0V7GB
|
||||
| Former ID |
DIB015881
|
||||
| Drug Name |
MMP-13 inhibitors
|
||||
| Synonyms |
MMP-13 inhibitors (osteoarthritis); MMP-13 inhibitors (osteoarthritis), AstraZeneca; Metalloprotease-13 (osteoarthritis), AstraZeneca
|
||||
| Indication | Osteoarthritis [ICD9: 715; ICD10:M15-M19, M47] | Investigative | [552130] | ||
| Company |
AstraZeneca plc
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
[C@]1([C@H]2CCN(C1)CC2)(C#Cc1ccc(Oc2ccc(C(=O)NCc3ncncc3<br />)cc2)cc1)O
|
||||
| Target and Pathway | |||||
| Target(s) | Collagenase 3 | Target Info | Inhibitor | [528284], [536172] | |
| NetPath Pathway | IL1 Signaling Pathway | ||||
| PANTHER Pathway | Alzheimer disease-presenilin pathway | ||||
| Plasminogen activating cascade | |||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| References | |||||
| Ref 528284 | Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol. 2006 Jul 4;48(1):15-20. Epub 2006 Jun 21. | ||||
| Ref 536172 | Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7. Epub 2006 Jan 20. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.